Primary pulmonary hypertension: a vascular biology and translational research "Work in progress".
Primary pulmonary hypertension (PPH) is a syndrome of dyspnea, chest pain, and syncope defined by increased pulmonary vascular resistance and the absence of a known cause. It also occurs in a familial form, which is linked to unidentified genes on chromosome 2. This syndrome is characterized by abnormalities of pulmonary vascular biology in each compartment of the blood vessel. The lumen has a prothrombotic diathesis, the endothelium displays an excessive production of vasoconstrictors relative to vasodilators, and the smooth muscle cells are depolarized and calcium-overloaded, which is due in part to reduced expression of voltage-gated potassium channels (Kv). This causes vasoconstriction and may promote cell proliferation. The adventitia displays excessive remodeling, which is associated with exaggerated metalloproteinase and elastase activity. Conceptually, PPH seems to require a permissive genotype, a susceptible phenotype (eg, endothelial dysfunction) and, in many cases, an exogenous trigger (eg, an anorexigen). Although there is not a generally accepted, unifying hypothesis regarding its cause, impaired function and the expression of vascular and platelet Kv channels suggest PPH may be a disease of the ion channels. Abnormal matrix metalloproteinase and elastase activity could also explain the abnormal vascular tone, platelet activation, and remodeling in PPH. Although calcium-channel blockers and prostacyclin, particularly when coadministered with warfarin, improve survival, PPH has a 5-year mortality rate of approximately 50%. Pharmacological and gene therapies aimed at enhancing the activity of prostacyclin, nitric oxide synthases, and Kv channels or at inhibiting endothelin and matrix metalloproteinases are promising areas for future development.
Archer
S
S
Division of Cardiolgy, Department of Medicine, University of Alberta, WMC 2C2.36,8440, Edmonton, Alberta, Canada. sarcher@cha.ab.ca.
Rich
S
S
D000925:Anticoagulants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D009569:Nitric Oxide / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000473:pathology / Q000503:physiopathology
D000925:Anticoagulants; D002121:Calcium Channel Blockers; D011453:Prostaglandins; D009569:Nitric Oxide